16 results about "Immunity active" patented technology

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

This invention belongs to the field of biomedical technology, specifically disclosing the application of a CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid in the preparation of a drug for treating tumors. Through analysis of the COSMIC database, epitope prediction, and in vitro and in vivo immunomodulatory activity experiments, this invention identified an HLA-A2-restricted CTL epitope peptide derived from the neoantigen ESR1. This mutant epitope peptide originates from a high-frequency mutation of ESR1 and can effectively stimulate and induce the production of neotope-specific cytotoxic T lymphocytes, specifically distinguishing between wild-type and mutant sequences, and killing tumor cells expressing the mutant epitope, exhibiting good anti-tumor effects. The resulting drug for treating tumors may contain the CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid, or may contain a T-cell receptor, chimeric antigen receptor, or its encoded nucleic acid that specifically recognizes the mutant epitope peptide, demonstrating good therapeutic potential and clinical application prospects.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.

An anticancer agent is provided comprising, as active ingredients, NK cells and a fusion protein comprising an IL-2 protein and a CD80 protein. In one specific formulation, a fusion protein comprising a CD80 fragment, an immunoglobulin Fc region, and an IL-2 variant can activate immune cells such as natural killer cells. Furthermore, since the pharmaceutical composition can effectively inhibit cancer, when co-administered with natural killer cells, it increases immune activity in the body, making it effective for cancer treatment and thus highly applicable to industry.

This invention discloses a porcine CD40L trimer protein, a recombinant Bacillus subtilis strain expressing this protein, and its applications, belonging to the fields of microbial genetic engineering and livestock and poultry biological products technology. This invention utilizes Bacillus subtilis WB800N as a host and pHT43 as a vector to successfully construct a recombinant strain that efficiently secretes and expresses porcine CD40L trimer protein. Soluble expression of the porcine CD40L trimer protein was achieved. The amino acid sequence of the porcine CD40L trimer protein expressed by the recombinant strain is shown in SEQ ID NO:1. Immunological activity verification using this porcine CD40L trimer protein revealed that the CD40L trimer protein expressed in this invention can simultaneously activate humoral and cellular immunity, possessing practical application value as a novel vaccine adjuvant.

An mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one Mycobacterium tuberculosis early-secreted antigen or an immunologically active fragment thereof; Mycobacterium tuberculosis PE / PPE family antigen Rv3872 or an immunologically active fragment thereof; and at least one Mycobacterium tuberculosis latency-associated antigen or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which can be used not only as a prophylactic vaccine for preventing latency activation, but also as a therapeutic drug for treating active tuberculosis, and has a significant inhibitory effect on Mycobacterium tuberculosis.

An mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one Mycobacterium tuberculosis early-secreted antigen or an immunologically active fragment thereof; at least one Mycobacterium tuberculosis PE / PPE family antigen or an immunologically active fragment thereof; and at least one Mycobacterium tuberculosis latency-associated antigen or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which can be used not only as a prophylactic vaccine for preventing latency activation, but also as a therapeutic drug for treating active tuberculosis, and has a significant inhibitory effect on Mycobacterium tuberculosis.

This invention discloses an extracellular polysaccharide DSP-1 from the shell of a deep-sea fungus, *Subseptospora*, and its applications. Didymella keratinophila The fermentation product of SCAU273 was isolated and purified to obtain an extracellular polysaccharide DSP-1. This polysaccharide has a molecular weight of 4116 Da, a bibranched structure, and is mainly composed of glucose polymers. Further studies showed that DSP-1 can enhance the activity and promote the proliferation of RAW 264.7 macrophages over a wide concentration range (25–400 μg / mL). Furthermore, at certain concentrations, it dose-dependently promoted the secretion of NO, TNF-α, IL-6, and IL-1β by RAW 264.7 macrophages, exhibiting good immunomodulatory activity against RAW 264.7 macrophages. It shows broad prospects for the production and widespread application of environmentally friendly marine biological agents.

This invention provides a deep learning-based method for dynamically optimizing the metabolic feedback immune activity of fermented feed, comprising the following steps: S1: Collection of basic data and immune activity indicators of fermented feed; S2: Data preprocessing and feature engineering; S3: Construction of a deep learning-based immune activity prediction model; S4: Construction of a fusion framework driven by chaotic mapping—slime mold algorithm, symbiotic organism search, and fruit fly optimization algorithm; S5: Dynamic optimization of fermentation parameters based on the fusion algorithm; S6: Construction of a metabolic feedback mechanism and verification of optimization results. This invention overcomes the technical problems of inaccurate parameter control, limited optimization algorithms, lack of metabolic feedback, and insufficient immune activity prediction in existing fermented feed production.

Provided herein are IL-10 variant sequences. In some embodiments, the IL-10 variants are immunosilent, and / or are capable of suppressing monocyte, macrophage, or pDC activity. Also disclosed herein are vaccines comprising the IL-10 variants, and methods of treatment for diseases and disorders that correspond with activating adaptive immunity.

The present application belongs to the technical field of compound feed for marine fish, and particularly relates to a feed for enhancing the immune activity of Hexagrammos otakii and a preparation method thereof. The feed is prepared from the following raw materials in mass percentage: base ingredients 93.5-96.5%, compound vitamins 1%, compound mineral salts 1%, and compound feed composition 1.5-4.5%, with the sum of the mass percentages of the raw materials being 100%; the immune activity composition is prepared from dried orange peel, betaine, and yucca extract, and the mass ratio of the dried orange peel, betaine, and yucca extract is 1-3:1-3:1-2. The feed for enhancing the immune activity of Hexagrammos otakii provided by the present application, through the synergistic effect of dried orange peel, betaine, and yucca extract, not only optimizes the digestion process of Hexagrammos otakii, but also comprehensively improves the health level and immune activity of Hexagrammos otakii from multiple aspects of antibiosis, immune enhancement, and anti-inflammation.

The application discloses a polycyclic aromatic hydrocarbon antigen and application thereof, and belongs to the field of immunology. The polycyclic aromatic hydrocarbon antigen is a BKF antigen, wherein the BKF antigen comprises a BKF-BSA coating antigen and a BKF-KLH immunogen; and the BKF hapten is a coupling arm and an active-COC2H4COOH group introduced on a benzene ring of the BKF hapten. The application guarantees that a BKF characteristic structure is recognized by an immunocompetent cell, facilitates the establishment of a specific BKF antibody, is used for rapid screening and detection of the BKF, provides a basis for the application of the BKF commercialized rapid detection antibody, and has a high application prospect.

The application belongs to the technical field of biotechnology, and discloses a vaccine adjuvant containing LLOMe, a vaccine composition and application thereof. The application uses LLOMe as a vaccine adjuvant, which can enhance the activity of dendritic cells (DCs) when used in combination with a vaccine, promote the promotion of vaccine antigens, and improve the prevention and treatment effect of the vaccine. The application first discloses the technical content of LLOMe as a vaccine adjuvant, and the vaccine obtained by combining LLOMe with antigens can significantly enhance the anti-tumor cell immunity, thereby obtaining effective immune activity and treatment effect.

This application provides a method for establishing and applying mouse gastric squamous cell carcinoma cell lines and gastric cancer-related fibroblast cell lines. The culture medium for culturing these cell lines comprises L-WRN cell culture supernatant, and 100×N-2 additive (0.5 vol%–1.5 vol%), 50× vitamin A-free B-27 additive (1.5 vol%–2.5 vol%), N-acetylcysteine ​​amide (1 mM–1.5 mM), nicotinamide (8 mM–12 mM), FGF-10 (80 ng / mL–120 ng / mL), EGF (40 ng / mL–60 ng / mL), A83-01 (0.8 μM–1.2 μM), Y-27632 dihydrochloride (8 μM–12 μM), Glutamax additive (0.5 vol%–1.5 vol%), and Matrigel. The culture medium provided in this application contains 5 vol%–7 vol% Hepes buffer (8 mM–12 mM) and gastrin (0.8 nM–1.2 nM). This medium can significantly improve the success rate of in vitro culture of primary cell lines. The mouse gastric squamous cell carcinoma cell lines and gastric cancer-related fibroblast cell lines obtained from this medium are genetically stable and can be used to construct ectopic or orthotopic implantation models in immune-active mice.

This invention discloses a method for preparing platelet lysis buffer and its application, belonging to the field of cell biotechnology. The invention employs X-ray irradiation inactivation technology, irradiating plasma supernatant at a dose of 25-35 kGy under low-temperature and light-protected conditions (2-8℃) to thoroughly inactivate immunologically active substances and pathogenic microorganisms, while avoiding thermal denaturation of growth factors. This is combined with segmented ultrasonic cyclic lysis and ice-water bath temperature control (≤37℃) to ensure complete platelet lysis and reduce damage to active factors. Further treatment with calcium gluconate removes fibrin, preventing the precipitation of flocculent material. The preparation method of this invention is process-controllable and highly safe, with a core growth factor retention rate ≥80% and a fibrin removal rate exceeding 92%. The prepared platelet lysis buffer can be added to mesenchymal stem cell culture medium, effectively meeting the high-quality requirements of clinical-grade cell culture.

Disclosed is a method for determining immune activity of a subject, the method comprising a determination step for determining immune activity of the subject on the basis of the amount of at least one biomarker in urine collected from the subject.